Document is current

Article History

Received: 16 December 2023

Accepted: 1 February 2024

First Online: 6 February 2024

Declarations

:

: The prospective HSSG study protocol was approved by the Ethics Committees of the participating hospitals, and patients were enrolled after written informed consent provided by themselves or their first-degree relatives (see Additional file : Methods for a list of approvals). The SUPERIOR study protocol was approved by the Ethics Committees of the participating hospitals (approval 276/03-05-2018 by ATTIKON University General Hospital; approval 1060/05-12-2018 by Rion University General Hospital), by the National Ethics Committee of Greece (106/24-07-2018) and by the National Organization for Medicines of Greece (approval 141/ 21-05-2020).

: Not applicable.

: EJG-Β has received honoraria from Abbott Products Operations, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH and Sobi; independent educational grants from Abbott Products Operations, AbbVie, bioMérieux Inc, InCyte, Johnson & Johnson, MSD, UCD and Sobi; and funding from the Horizon 2020 Marie Skłodowska-Curie International Training Network “the European Sepsis Academy” (granted to the National and Kapodistrian University of Athens), the Horizon 2020 European Grants ImmunoSep and RISC in COVID and the Horizon Health grant EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis). JE-O is a co-founder, shareholder and CSO of ViroGates, Denmark, and named inventor on patents on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark. The other authors do not disclose any conflict of interest.